← Leaderboards
Yangbo Feng
Scripps Florida
$2,398,730
Attributed
$4,797,459
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $851.9K · FY2011–21$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,797,459 · 2
By mechanism
R01$4,203,459 · 1
R21$594,000 · 1
Top collaborators
- Sung Ok Yoon5 shared
- Philip Lograsso2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposInhibitor/AntagonistPharmaceutical PreparationsBasePhosphotransferasesPhosphorylationProtein IsoformsPropertySmall MoleculeCellsDesignS DiseaseBrainBiochemicalDrug DiscoveryCoupledCognitionBasic ScienceCognitive AbilityCell LineCachexiaBody Weight DecreasedBackClinical Research
Grant awards (7)
Preclinical drug development of isoform selective JNK3 inhibitors for Alzheimer's disease.$837,118
R01 · FY2021 · AG
Preclinical drug development of isoform selective JNK3 inhibitors for Alzheimer's disease.$837,118
R01 · FY2020 · AG
Preclinical drug development of isoform selective JNK3 inhibitors for Alzheimer's disease.$837,118
R01 · FY2019 · AG
Preclinical drug development of isoform selective JNK3 inhibitors for Alzheimer's disease.$840,205
R01 · FY2018 · AG
Preclinical drug development of isoform selective JNK3 inhibitors for Alzheimer's disease.$851,900
R01 · FY2017 · AG
Development of small molecule Limk inhibitors for probing ocular diseases$297,000
R21 · FY2012 · EY · contact PI
Development of small molecule Limk inhibitors for probing ocular diseases$297,000
R21 · FY2011 · EY · contact PI